Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jesús Troya

Showing results (1-10 of 56) with videos related to

Pageof 6
Sort By:
AIDS Reviews|September 22, 2016
Safety and Tolerability: Current Challenges to Antiretroviral Therapy for the Long-Term Management of HIV InfectionJesús Troya, José Bascuñana
European Geriatric Medicine|October 15, 2021
Geriatric-HIV Medicine: the geriatrician's roleFátima Brañas, Pablo Ryan, Jesús Troya, et al.
Scandinavian Journal of Infectious Diseases|September 14, 2007
Long term failure of miltefosine in the treatment of refractory visceral leishmaniasis in AIDS patientsJesús Troya, Angela Casquero, Elena Refoyo, et al.
Computer Methods and Programs in Biomedicine|May 29, 2024
Artificial intelligence model for tumoral clinical decision support systemsGuillermo Iglesias, Edgar Talavera, Jesús Troya, et al.
Open Forum Infectious Diseases|September 27, 2017
Infliximab Biosimilars: A Promising but Unusual Treatment for Mycobacterial Immune Reconstitution Inflammatory Syndrome in Human Immunodeficiency Virus-Infected PatientsJesús Troya, Guillermo Cuevas, Pablo Ryan, et al.
AIDS (London, England)|March 22, 2018
High HIV seroconversion rate in hepatitis C virus-infected drug users followed in a harm reduction unit: a lost opportunity for preexposure prophylaxisJorge Valencia, Pablo Ryan, Alejandro Alvaro-Meca, et al.
Journal of Clinical Medicine|February 11, 2023
Predict the Effects of Dolutegravir (DTG) Plus Lamivudine (3TC) on Immunological Responses in People Living with HIV (PLWHIV)Jesús Troya, Roberto Pedrero-Tomé, Luis Buzón, et al.
Plos One|October 4, 2018
HCV seroconversion in a cohort of people who use drugs followed in a mobile harm reduction unit in Madrid: Breaking barriers for HCV eliminationJorge Valencia La Rosa, Pablo Ryan, Alejandro Alvaro-Meca, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|November 12, 2021
Differences in the hepatitis C virus cascade of care and time to initiation of therapy among vulnerable subpopulations using a mobile unit as point-of-careJorge Valencia, Jeffrey V Lazarus, Francisco C Ceballos, et al.
International Journal of STD & AIDS|July 7, 2020
Health care issues affecting transgender people living with HIV: an opportunity for improvementJesús Troya, Jorge Del Romero, Pablo Ryan, et al.
Pageof 6

Showing results (1-10 of 56) with videos related to

Sort By:
Pageof 6
AIDS Reviews|September 22, 2016
Safety and Tolerability: Current Challenges to Antiretroviral Therapy for the Long-Term Management of HIV InfectionJesús Troya, José Bascuñana
European Geriatric Medicine|October 15, 2021
Geriatric-HIV Medicine: the geriatrician's roleFátima Brañas, Pablo Ryan, Jesús Troya, et al.
Scandinavian Journal of Infectious Diseases|September 14, 2007
Long term failure of miltefosine in the treatment of refractory visceral leishmaniasis in AIDS patientsJesús Troya, Angela Casquero, Elena Refoyo, et al.
Computer Methods and Programs in Biomedicine|May 29, 2024
Artificial intelligence model for tumoral clinical decision support systemsGuillermo Iglesias, Edgar Talavera, Jesús Troya, et al.
Open Forum Infectious Diseases|September 27, 2017
Infliximab Biosimilars: A Promising but Unusual Treatment for Mycobacterial Immune Reconstitution Inflammatory Syndrome in Human Immunodeficiency Virus-Infected PatientsJesús Troya, Guillermo Cuevas, Pablo Ryan, et al.
AIDS (London, England)|March 22, 2018
High HIV seroconversion rate in hepatitis C virus-infected drug users followed in a harm reduction unit: a lost opportunity for preexposure prophylaxisJorge Valencia, Pablo Ryan, Alejandro Alvaro-Meca, et al.
Journal of Clinical Medicine|February 11, 2023
Predict the Effects of Dolutegravir (DTG) Plus Lamivudine (3TC) on Immunological Responses in People Living with HIV (PLWHIV)Jesús Troya, Roberto Pedrero-Tomé, Luis Buzón, et al.
Plos One|October 4, 2018
HCV seroconversion in a cohort of people who use drugs followed in a mobile harm reduction unit in Madrid: Breaking barriers for HCV eliminationJorge Valencia La Rosa, Pablo Ryan, Alejandro Alvaro-Meca, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|November 12, 2021
Differences in the hepatitis C virus cascade of care and time to initiation of therapy among vulnerable subpopulations using a mobile unit as point-of-careJorge Valencia, Jeffrey V Lazarus, Francisco C Ceballos, et al.
International Journal of STD & AIDS|July 7, 2020
Health care issues affecting transgender people living with HIV: an opportunity for improvementJesús Troya, Jorge Del Romero, Pablo Ryan, et al.
Pageof 6